Copyright
©The Author(s) 2022.
World J Diabetes. Feb 15, 2022; 13(2): 70-84
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.70
Published online Feb 15, 2022. doi: 10.4239/wjd.v13.i2.70
Table 1 Definitions of metabolic health in previous publications
Ref. | BP, kPa (mmHg) | Plasma glucose, mmol/L | TG, mmol/L | HDL-C, mmol/L | LDL-C, mmol/L | TC, mmol/L | WC, cm | Insulin sensitivity | CRP, mg/L | Intrahepatic lipid content | Others | Metabolic health | |
NECP ATP III[9] | SBP ≥ 17.3 (130) and/or DBP ≥ 11.3 (85) and/or treatment | FPG ≥ 5.60 | ≥ 1.70 | < 1.29 in women, < 1.03 in men | - | - | > 88 in women, >102 in men | - | - | - | - | < 3 of above | |
Karelis et al[17] | - | - | ≤ 1.70 | ≥ 1.30 and no treatment | ≤ 2.60 and no treatment | ≤ 5.20 | - | HOMA-IR ≤ 1.95 | - | - | - | > 3 of above | |
Meigs et al[4] | SBP ≥ 17.3 (130) or DBP ≥ 11.3(85) or treatment | 5.6 < FPG ≤ 6.9 | ≥ 1.70 | < 1.30 in women, < 1.00 in men | - | - | > 88 in women, > 102 in men | - | - | - | - | < 2 of above | |
Meigs et al[4] | - | - | - | - | - | - | - | HOMA-IR ≥ 75th percentile | - | - | - | None of above | |
Aguilar-Salinas et al[89] | SBP > 18.6 (140) and/or DBP > 12.0 (90) and/or treatment | FPG ≥ 7.0, or 2-h OGTT ≥ 11.1, or RBG ≥ 11.11 or treatment | - | < 1.04 | - | - | - | - | - | - | - | None of above | |
Wildman et al[18] | SBP ≥ 17.3 (130) or DBP ≥ 11.3 (85) or treatment | FPG ≥ 5.56 or treatment | ≥ 1.70 | < 1.30 in women, < 1.04 in men or treatment | - | - | - | HOMA-IR > 90th percentile | > 90th percentile | - | - | < 2 of above | |
van Vliet-Ostaptchouk et al[90] | SBP ≥ 17.3 (130) or DBP ≥ 11.3 (85) or treatment | FPG ≥ 6.10 or treatment or history/diagnosis of type 2 diabetes | ≥ 1.70 or treatment | < 1.03 in men or < 1.30 in women or treatment | - | - | - | - | - | - | - | <2 of above | |
Jana V van Vliet-Ostaptchouk et al[90] | SBP ≥ 18.6 (140) or DBP ≥ 12.0(90) or treatment | FPG ≥ 7.0 or treatment or history/diagnosis of type 2 diabetes | ≥ 1.70 or treatment | < 1.03 in men or < 1.30 in women or treatment | - | - | - | - | - | - | - | < 2 of above | |
Smith et al[20] | SBP < 17.3 (130) and/or DBP < 11.3 (85) | FPG < 5.60, or 2-h OGTT glucose < 7.80 | < 1.07 | ≥ 1.29 in women, ≥ 1.04 in men | - | - | - | GIR > 8 mg/kg FFM/min during an HECP (insulin infusion rate: 40 mU/m2/min) | - | < 5% of liver volume by imaging or < 5% of hepatocytes with intracellular TG by histology | Basic criteria: Absence of diagnosis or therapy of cardiometabolic diseases | all of above |
- Citation: Wu Q, Xia MF, Gao X. Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus? World J Diabetes 2022; 13(2): 70-84
- URL: https://www.wjgnet.com/1948-9358/full/v13/i2/70.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i2.70